What is Ultram and the way is it used?

Ultram may be a medicinal drug prescribed to treat symptoms of moderate to severe pain. Ultram could also be used alone or with different medications.

Ultram belongs to a category of medicine referred to as Opioid Analgesics.

It is not celebrated if Ultram is safe and effective in youngsters younger than seventeen years aged.

Ultram might cause negative effects including:

  • noisy respiration,
  • sighing,
  • shallow respiration,
  • breathing that stops throughout sleep,
  • slow rate or weak pulse,
  • lightheadedness,
  • seizure (convulsions),
  • nausea,
  • vomiting,
  • loss of craving,
  • dizziness, and
  • worsening fatigue or weakness

Get medical facilitate directly, if you’ve got any of the symptoms listed on top of.

The most common effects of Ultram include:

  • constipation,
  • nausea,
  • vomiting,
  • stomach pain,
  • dizziness,
  • drowsiness,
  • tiredness,
  • headache, and
  • itching

Tell the doctor if you’ve got any facet result that bothers you or that doesn’t flee.

These aren’t all the doable facet effects of Ultram. For a lot of info, raise your doctor or apothecary.


Drug Substance

Proper name: tramadol coordination compound

Chemical name: (±)cis-2-[(dimethylamino)methyl]-1-(3-methoxyphenyl) alcohol coordination compound

Molecular formula and molecular mass: C16H25NO2 •HCl and 299.84

Physicochemical properties: Tramadol coordination compound may be a white to off-white, crystalline, scentless powder with a freezing point between 180-184°C.


ULTRAM is indicated in adults for the management of pain severe enough to want associate degree opioid analgesic and that various treatments square measure inadequate.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at suggested doses [see WARNINGS AND PRECAUTIONS], reserve ULTRAM to be used in patients for whom various treatment choices [e.g., non-opioid analgesics]:

Have not been tolerated or aren’t expected to be tolerated.

Have not provided adequate physiological state or aren’t expected to supply adequate physiological state.


Important indefinite quantity And Administration directions

Do not use ULTRAM concomitantly with different tramadol-containing product.

Do not administer ULTRAM at a dose olympian four hundred mg per day.

Do not administer ULTRAM at a dose olympian four hundred mg per day.

Initiate the dosing regimen for every patient severally, taking into consideration the patient’s severity of pain, patient response, previous analgesic treatment expertise, and risk factors for addiction, abuse, and misuse.

Monitor patients closely for metabolism depression, particularly among the primary 24-72 hours of initiating medical care and following indefinite quantity will increase with ULTRAM and regulate the indefinite quantity consequently.

Initial indefinite quantity

Initiating Treatment with Ultram

For patients not requiring speedy onset of analgesic result, the tolerability of ULTRAM may be improved by initiating medical care with the subsequent volumetric analysis regimen: begin ULTRAM at 25mg/day and titrated in twenty five mg increments as separate doses each three days to achieve one hundred mg/day (25mg fourfold a day). thenceforth the entire daily dose could also be redoubled by fifty mg as tolerated each three days to achieve two hundred mg/day (50 mg fourfold a day). when volumetric analysis, ULTRAM fifty to one hundred mg may be administered for pain relief each four to six hours to not exceed four hundred mg/day.

For the set of patients for whom speedy onset of analgesic result is needed and for whom the advantages outweigh the chance of ending thanks to adverse events related to higher initial doses, ULTRAM fifty mg to one hundred mg may be administered for pain relief each four to 6 hours, to not exceed four hundred mg per day.

Conversion from Ultram To Extended-Release Tramadol

The relative bioavailability of ULTRAM compared to extended-release tramadol is unknown, thus conversion to extended-release formulations should be in the course of shut observation for signs of excessive sedation and metabolism depression.

Dosage Modification in Patients With viscus Impairment

The suggested dose for adult patients with severe viscus impairment is fifty mg each twelve hours.

Dosage Modification in Patients With urinary organ Impairment

In all patients with creatinine clearance but thirty mL/min, it’s suggested that the dosing interval of ULTRAM be redoubled to twelve hours, with a most daily dose of two hundred mg. Since solely seven-membered of associate degree administered dose is removed by hemodialysis, chemical analysis patients will receive their regular dose on the day of chemical analysis.

Dosage Modification in Geriatric Patients

Do not exceed a complete dose of three hundred mg/day in patients over seventy-five years recent.

Titration and Maintenance of medical care

Individually quantify ULTRAM to a dose that has adequate physiological state and minimizes adverse reactions. frequently assess patients receiving ULTRAM to assess the upkeep of pain management and therefore the relative frequency of adverse reactions, further on monitor for the event of addiction, abuse, or misuse. Frequent communication is very important among the prescriber, different members of the aid team, the patient, and therefore the caregiver/family in periods of fixing analgesic necessities, as well as initial volumetric analysis.

If the amount of pain will increase when indefinite quantity stabilization, plan to determine the supply of redoubled pain before increasing the ULTRAM indefinite quantity. If unacceptable opioid-related adverse reactions square measure determined, contemplate reducing the indefinite quantity. regulate the indefinite quantity to get associate degree applicable balance between management of pain and opioid-related adverse reactions.

Discontinuation of Ultram

When a patient has been taking ULTRAM often and will be physically dependent now not needs medical care with ULTRAM, taper the dose bit by bit, by twenty fifth to five hundredth each a pair of to four days, whereas watching rigorously for signs and symptoms of withdrawal. If the patient develops these signs or symptoms, raise the dose to the previous level and taper a lot of slowly, either by increasing the interval between decreases, decreasing the number in dosage, or both.


The following serious adverse reactions unit described, or described in larger detail, in several sections:

  • Addiction, Abuse, and Misuse
  • Life-Threatening metabolism Depression
  • Ultra-Rapid Metabolism of Tramadol and totally different Risk Factors for grave metabolism Depression in children
  • Interactions with Benzodiazepines or totally different CNS Depressants
  • Serotonin Syndrome
  • Seizures
  • Suicide
  • insufficient adrenal
  • Severe disorder
  • Gastrointestinal Adverse Reactions
  • Hypersensitivity Reactions
  • Withdrawal
  • Clinical Trials experience

ULTRAM was administered to 550 patients throughout the double-blind or open-label extension periods in U.S. studies of chronic benign pain. of these patients, 375 were sixty 5 years recent or older. Table one reports the additive incidence rate of adverse reactions by seven, thirty and ninety days for the foremost frequent reactions (5% or extra by seven days). the foremost oftentimes reported   events were among the central nervous system and system. although the reactions listed among the table unit felt to be presumably related to ULTRAM administration, the reported   rates together embrace some events which will area unit attributable to underlying health problem or concomitant medication. the incidence rates of adverse experiences in these trials were similar for ULTRAM and conjointly the active management groups, pain pill with anodyne #3 (acetaminophen 300 mg with anodyne phosphate thirty mg), and aspirin 325 mg with anodyne phosphate thirty mg, however, the rates of withdrawals attributable to adverse events gave the impression to be higher among the ULTRAM groups.

The following lists adverse reactions that occurred with Associate in Nursing incidence of 1 Chronicles to however ball in clinical trials, which the probability of a contributive relationship with ULTRAM exists.

  • Body as a Whole: discomfort.
  • Cardiovascular: dilation.
  • Central Nervous System: Anxiety, Confusion, Coordination disturbance, Euphoria, Miosis, Nervousness, upset.
  • Gastrointestinal: Abdominal pain, Anorexia, Flatulence.
  • Musculoskeletal: tone.
  • Skin: Rash.
  • Special Senses: Visual disturbance.
  • Urogenital: time symptoms, Urinary frequency, retention.

Incidence however 1 Chronicles, presumptively Causally connected

The following lists adverse reactions that occurred with Associate in Nursing incidence of however 1 Chronicles in clinical trials of tramadol and/or reported   in post-marketing experience with tramadol-containing product.

Body as a Whole: injury, sensitivity, hypersensitivity, Death, unsafe tendency, Weight loss, monoamine syndrome (mental standing modification, hyperreflexia, fever, shivering, tremor, agitation, activity, seizures and coma).

Cardiovascular: cardiovascular disease, Syncope, arrhythmia.

Central Nervous System: Abnormal gait, Amnesia, psychological feature pathology, Depression, drawback in concentration, Hallucinations, paresthesia, Seizure, Tremor.

Respiratory: symptom.

  • Skin: Stevens-Johnson syndrome/Toxic cuticular lysis, Urticaria, Vesicles.
  • Special Senses: Dysgeusia.
  • Urogenital: disorder, discharge disorder.

Other Adverse Experiences, contributive Relationship Unknown

A variety of various adverse events were reported generally in patients taking ULTRAM throughout clinical trials and/or reported   in post-marketing experience. A contributive relationship between ULTRAM and these events has not been determined. However, the foremost important events unit listed below as alerting information to the medical expert.

  • Cardiovascular: Abnormal graph, high force per unit area, disorder, heart muscle anemia, Palpitations, pulmonary oedema, embolism.
  • Central Nervous System: headache.
  • Gastrointestinal: GI hemorrhage, Hepatitis, Stomatitis, Liver failure.
  • Laboratory Abnormalities: Creatinine increase, Elevated liver enzymes, conjugated protein decrease, symptom.
  • Sensory: Cataracts, Deafness, Tinnitus.
  • Serotonin syndrome: Cases of monoamine syndrome, a probably grave condition, area unit reported   throughout concomitant use of opioids with serotonergic drugs.
  • Insufficient adrenal: Cases of adrenal insufficiency area unit reported   with opioid use, extra generally following larger than one month of use.

QT prolongation/torsade Diamond State pointes: Cases of QT prolongation and/or torsade Diamond State pointes area unit reported   with tramadol use. many of these cases were reported   in patients taking another drug labeled for QT prolongation, in patients with a risk issue for QT prolongation (e.g., hypokalemia), or among the dose setting.

Eye disorders – inborn reflex

Metabolism and nutrition disorders – Cases of symptom reported are very rarely in patients taking tramadol. Most reports were in patients with predisposing risk factors, beside congenital disease or uropathy, or in aged patients.

  • Nervous system disorders – movement disorder, defect of speech
  • Psychiatric disorders – delirium

Back to top button